Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines

Susan Zolla-Pazner, Carl Alving, Robert Belshe, Phillip Berman, Sherri Burda, Padmasree Chigurupati, Mary Lou Clements, Anne Marie Duliege, Jean Louis Excler, Catarina Hioe, James Kahn, M. Juliana McElrath, Sandra Sharpe, Faruk Sinangil, Kathelyn Steimer, Mary Clare Walker, Nabila Wassef, Serena Xu

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

The inability of antibodies induced by experimental human immunodeficiency virus type I (HIV-1) vaccines to neutralize HIV-1 primary isolates may be due to a failure to elicit such antibodies, antigenic differences between the vaccine and the strains tested, insensitivity of the assays used, or to a combination of factors. New neutralization assays were used to determine the ability of candidate AIDS vaccines to generate neutralizing antibodies for clade B primary isolate BZ167, which is closely related in portions of its envelope to the immunizing strains. Sera from HIV-uninfected volunteers in vaccine trials were tested, and neutralizing activity was found in recipients of recombinant (r) gp120(MN) or of rgp160(MN)-containing canarypox boosted with rgp120(SF-2). Detection of antibodies that neutralize primary isolate BZ167 correlated with neutralizing activity for homologous vaccine strains. These data demonstrate that certain candidate AIDS vaccines can elicit antibodies that neutralize a primary isolate of HIV-1.

Original languageEnglish
Pages (from-to)764-774
Number of pages11
JournalJournal of Infectious Diseases
Volume175
Issue number4
DOIs
StatePublished - 1997

Fingerprint

Dive into the research topics of 'Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines'. Together they form a unique fingerprint.

Cite this